Skip to main content

Oxford Science Enterprises — Portfolio, Page 5

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

134
Companies
$2.2B
Total invested
$18.0M
Avg. check
39
Industries
Biotechnology 9Health Care 7Medical 5Quantum Computing 5Life Science 5Hardware 4+33 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 97120 of 134
Oxford Endovascular
May 2024

Oxford Endovascular are developing a novel treatment for treating brain aneurysms.

Biotechnology · Oxford$10.2M Series A
Albus Health
January 2024

A med-tech startup that has developed a passive and contactless device for monitoring nocturnal symptoms and environmental metrics at home.

Biotechnology · OxfordSeries Unknown
Oxford Quantum Circuits
November 2023

Oxford Quantum Circuits develops quantum computers designed for breakthrough discoveries.

Hardware · Reading$100.0M Series B
Proxisense
November 2023

Proxisense has developed extreme environment proximity sensors and fluid contamination systems.

Hardware · Oxford$1.3M Series A
Sitryx Therapeutics
September 2023

Sitryx is a biopharmaceutical company develops disease modifying therapeutics in immuno-oncology and immuno-inflammation.

Biotechnology · Oxford$39.0M Series A
Oxford Ionics
August 2023

Oxford Ionics is a quantum computing startup that provides innovations for the development of accurate and dependable quantum computers.

Electronics · Oxford$2.5M Series Unknown
Prolific
July 2023

Building the most advanced global infrastructure for People Science.

Artificial Intelligence (AI) · Oxford$32.3M Series A
Covatic
May 2023

Covatic is the use of mobile based algorithms to bring smart personalisation to apps.

Apps · Oxford$5.0M Series A
OMass Therapeutics
May 2023

OMass Therapeutics is a drug discovery company exploiting novel mass spectrometry platforms to develop therapeutics.

Life Science · Oxford$12.5M Series B
SpyBiotech
March 2023

SpyBiotech Operators of a biotechnology platform intended to generate next-generation vaccines.

Biotechnology · Oxford$4.1M Grant
Quantrol Ox
March 2023

QuantrolOx is building automated machine learning-based control software for quantum technologies to tune, stabilize, and optimize qubits.

Information Technology · Espoo$3.7M Seed
Quantum Motion
February 2023

Quantum Motion is building a universal quantum computer in Silicon, using CMOS compatible processes.

Electronics · London$50.6M Series B
Oxford VR
February 2023

Oxford VR is an evidence-based immersive treatment for serious mental illness and behavioral health.

Health Care · Oxford$500K Grant
Kesmalea Therapeutics
January 2023

Kesmalea Therapeutics is a biotech startup focusing on the discovery of novel protein degraders.

Biotechnology · London$6.0M Series A
BehaVR
December 2022

BehaVR develops evidence-based, immersive, digital therapeutics for behavioral health using Virtual Reality.

Health Care · Elizabethtown$13.0M Series B
Xerion Healthcare
November 2022

Xerion Healthcare is the technology commercialization company of University of Oxford.

Health Care · ThameGrant
Nucleome Therapeutics
October 2022

Nucleome Therapeutics is decoding the dark matter of the human genome to uncover novel ways to treat diseases

Biotechnology · Headington$42.0M Series A
BibliU
September 2022

BibliU provides colleges and universities with digital content management, automation, and an analytics platform.

E-Learning · London$1.4M Series B
Opsydia
September 2022

Opsydia is set to disrupt a number of industries by its ability to create practically invisible structures inside transparent materials.

Electronics · Oxford$4.0M Series Unknown
MiroBio
June 2022

MiroBio is Harnessing the natural control mechanisms of the immune system.

Biotechnology · Oxford$97.0M Series B
ORCA Computing
June 2022

ORCA Computing is building the first scalable and flexible quantum computer powered by photonics.

Computer · London$15.0M Series A
Scenic Biotech
March 2022

Scenic Biotech is a developer of a genomics and immunotherapy technologies created to unlock genetic suppressors.

Biometrics · Amsterdam$31.0M Series A
Alethiomics
December 2021

Alethiomics is a biotech company harnessing the power of single-cell multi-omic technology to discover & develop treatment for blood cancer.

Biotechnology · Headington$8.0M Seed
Rey
July 2021

Rey is a mental health and wellness company integrating immersive tools and digital interventions with teletherapy

Health Care · Austin$10.0M Series A

Where Oxford Science Enterprises invests

Biotechnology9
Health Care7
Medical5
Quantum Computing5
Life Science5
Hardware4

About Oxford Science Enterprises's portfolio

How many companies has Oxford Science Enterprises invested in?

Oxford Science Enterprises has invested in 134 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does Oxford Science Enterprises invest in?

Oxford Science Enterprises's top investment sectors include Biotechnology, Health Care, Medical, Quantum Computing, Life Science. The firm invests across 39 different industry categories.

What is Oxford Science Enterprises's largest investment?

Among tracked funding rounds, Oxford Quantum Circuits received $100.0M in a Series B round. Oxford Science Enterprises's total known invested capital is $2.2B.

What is the average investment size for Oxford Science Enterprises?

Oxford Science Enterprises's average investment size is $18.0M across its portfolio of 134 companies.

What are Oxford Science Enterprises's most recent investments?

Recent Oxford Science Enterprises portfolio additions include Oxford Endovascular, Albus Health, Oxford Quantum Circuits, Proxisense, Sitryx Therapeutics. These companies were founded in 2020 or later.

Reach the founders behind these 134 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →